AstraZeneca PLC (AZN)vsHumacyte Inc (HUMA)
AZN
AstraZeneca PLC
$173.30
-1.13%
HEALTHCARE · Cap: $261.94B
HUMA
Humacyte Inc
$0.62
-0.97%
HEALTHCARE · Cap: $187.05M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 2997866% more annual revenue ($60.44B vs $2.02M). AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
HUMA
Avoid14
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.7%
Fair Value
$193.96
Current Price
$173.30
$20.66 discount
Margin of Safety
+44.2%
Fair Value
$1.81
Current Price
$0.62
$1.19 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.9%
Generating 2.1B in free cash flow
No standout strengths identified
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Trading at 12.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : HUMA
HUMA has a balanced fundamental profile.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : HUMA
The primary concerns for HUMA are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 5.67 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while HUMA is a value play — different risk/reward profiles.
HUMA carries more volatility with a beta of 2.52 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 14/100), backed by strong 17.2% margins and 12.5% revenue growth. HUMA offers better value entry with a 44.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Humacyte Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Humacyte Inc (HUMA) is a pioneering biotechnology company specializing in vascular and regenerative medicine, with a focus on the development of human acellular vessels (HAVs). These innovative off-the-shelf products address critical needs in vascular reconstruction and chronic disease management, enhancing patient outcomes while potentially lowering healthcare costs. Utilizing its advanced technology platform, Humacyte is strategically positioned to lead advancements in transplantation and tissue engineering, solidifying its role as a transformative force in the evolving medical therapies landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?